Photodynamic therapy (PDT) is a promising therapeutic for some cancers due to decreased side effects in comparison to conventional chemotherapy. The photosensitizer, phthalocyanine, has been identified as a second-generation photosensitizer that has demonstrated potential for use in PDT. This project is aimed at developing a drug delivery system using a metal organic framework (MOF), MIL-68 (Al) NH<sub>2</sub>, and phthalocyanine to be used in photodynamic therapy. Currently an antibody, immunoglobulin G (IgG), immobilized on phthalocyanine@MIL-68 (Al) NH<sub>2 </sub>is being investigated as a potential targeting mechanism. Results of this study will be presented.

Developing a metal organic framework drug delivery system for use in photodynamic therapy

Fall 2022 abstracts, posters, and presentations will launch in mid-September.

ACS Fall 2022

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.